文献速递肿瘤 PET/CT骨显像与常规 SPECT

与PSMA靶向示踪剂相关的非特异性骨摄取的「小矮人」:基于系统评价的定义

The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-06-17

本系统评价探讨前列腺癌(PCa)患者接受PSMA靶向PET显像时非特异性骨摄取(UBU)的患病率、地形分布及临床意义,结果显示UBU患病率随放射性药物不同为0至71.7%,[18F]PSMA-1007最高;肋骨为所有示踪剂最常见部位,UBU平均SUVmax为3.4至7.7且一般低于骨转移。

要点

  • PSMA-PET中UBU患病率因示踪剂而异,范围为0至71.7%,[18F]PSMA-1007最高。
  • 肋骨是所有PSMA靶向示踪剂UBU最主要部位,脊柱或骨盆为第二常见部位。
  • UBU平均SUVmax为3.4至7.7,一般低于骨转移。

核心结论

  • 研究结果强调需提高对UBU的认识并精确解读,以避免潜在的过度分期及后续不恰当治疗决策。
  • 结合所用放射性药物、PET半定量参数、UBU地形分布及基于临床和实验室参数的验前概率准确评估,可能有助于核医学医师解读PSMA-PET结果。

研究设计与样本

  • 系统评价,按PRISMA方法筛选评估UBU患病率、地形分布及潜在临床意义的研究,并用QUADAS-2工具评价。

主要发现

  • PCa患者PSMA-PET扫描中UBU百分比范围为0至71.7%,取决于所用放射性药物,[18F]PSMA-1007显示最高发生率。
  • 肋骨是所有PSMA靶向放射性药物UBU的主要部位;脊柱是[68Ga]Ga-PSMA-11、[18F]DCFPyL、[18F]rhPSMA-7的第二常见UBU部位,骨盆带是[18F]PSMA-1007的第二常见部位。
  • UBU的平均最大标准化摄取值(SUVmax)为3.4至7.7,一般低于骨转移。

临床怎么用

  • 作者认为,考虑所用放射性药物、PET半定量参数、UBU地形分布及基于临床和实验室参数的验前概率,可能有助于核医学医师解读PSMA-PET结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-Specific Membrane Antigen (PSMA)-targeted Positron Emission Tomography (PET) has revolutionised prostate cancer (PCa) diagnosis and treatment, offering superior diagnostic accuracy over traditional methods and enabling theragnostic applications. However, a significant diagnostic challenge has emerged with identifying unspecific bone uptakes (UBUs), which could lead to over-staging and inappropriate treatment decisions if misinterpreted. This systematic review explores the phenomenon of UBUs in PCa patients undergoing PSMA-PET imaging. METHODS: Studies assessing the prevalence, topographical distribution, and potential clinical implications of UBUs were selected according to the Preferred Reporting Items for a Systematic Review and Meta-Analysis (PRISMA) method and evaluated with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. RESULTS: The percentage of PCa patients with UBUs on PSMA-PET scans ranged from 0 to 71.7%, depending on the radiopharmaceutical used, with [18F]PSMA-1007 showing the highest incidence. The ribs are the primary site of UBUs across all PSMA-targeted radiopharmaceuticals. The spine is the second most frequent UBU site for [68Ga]Ga-PSMA-11, [18F]DCFPyL, [18F]rhPSMA-7, while the pelvic girdle represents the second most frequent site for [18F]PSMA-1007. The average maximum Standardized Uptake Value (SUVmax) of UBUs varied from 3.4 to 7.7 and was generally lower than that of bone metastases. CONCLUSIONS: Our findings underscore the need for heightened awareness and precise interpretation of UBUs to avoid potential over-staging and subsequent inappropriate treatment decisions. Considering the radiopharmaceutical used, PET-derived semiquantitative parameters, the topographical distribution of UBUs, and accurately evaluating the pre-test probability based on clinical and laboratory parameters may aid nuclear medicine physicians in interpreting PSMA-PET findings.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Rizzo A, Morbelli S, Albano D, et al. The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging. 2024. PMID: 38884773. doi:10.1007/s00259-024-06797-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。